SHARE
Recombinant Deoxyribonucleic Acid Rdna Technology Market

Recombinant Deoxyribonucleic Acid (rDNA) Technology Market Forecasts to 2028 – Global Analysis By Component (Cloning Vector, Expression System), Application (Food & Beverages, Agriculture, Therapeutics) and By Geography

4.8 (80 reviews)
Published: February 2022 ID: SMRC20403
4.8 (80 reviews)
Published: February 2022 ID: SMRC20403

This report covers the impact of COVID-19 on this global market
Loading...

According to Stratistics MRC, the Global Recombinant Deoxyribonucleic Acid (rDNA) Technology Market is accounted for $155.79 billion in 2021 and is expected to reach $301.67 billion by 2028 growing at a CAGR of 9.9% during the forecast period. Recombinant DNA technology is a process in which creation and manipulation of the DNA sequences are in a specific order. This is resulting in the production of genetically modified organisms and products. Recombinant DNA technology (RDT) is essential for improving health conditions, primarily by developing new vaccines and pharmaceuticals.

Market Dynamics:

Driver:

Rising demand from various industries


Many industries are benefiting from the research conducted on genetically modified organisms (GMO), such as microorganisms that are considered as clean fuel producers and bio degraders. Genetically modified vaccines are developed for curing various diseases in humans and plants. The recombinant DNA technology created several potential innovation opportunities for developing a wide range of therapeutic products, with immediate effect in medical genetics and biomedicine, by modifying microorganisms, animals, and plants, in order to yield medically useful substances. Therefore, the increasing demand and application of RDT in various sectors are driving the growth of the market studied.

Restraint:

Risk associated with gene therapy


The global recombinant DNA technology market might face major restraints due to the risk associated with gene therapy. Another major restraint can be the stringent regulation for the approval of the product in various regions.

Opportunity:

Growth of genetic testing


In the North American and Western European regions, the genetic testing market grows larger, spreading its hands to many remote areas. Therefore, this can bring more opportunities for the service providers and companies to make the tests more affordable. Along with that, the global Recombinant DNA Technology Market is trying to enter the untapped regions to bring lucrative opportunities.

Threat:

Ethical considerations


The use of genetic modification technology has been a topic of controversies as a result of attendant ethical considerations in various applications such as gene therapy. In each of the diverse fields of medicine, agriculture, and environment, scientific and ethical concerns vary in a discipline-specific manner.

The expression system segment is expected to be the largest during the forecast period

Expression systems captured the largest share owing to the ongoing developments for efficient protein expression and for its further isolation on a large scale. Majorly used expression systems are mammalian, bacterial, insects, and yeast. The development of cell lines such as HEK293 and Chinese Hamster Ovarian (CHO) has contributed to the significant share of mammalian expression systems. In addition, ongoing research studies to explore the potential of plant as expression system are expected to drive the adoption of plan expression systems for GM product development in the coming years.

The agriculture segment is expected to have the highest CAGR during the forecast period

In agriculture, the development of genetically modified crops, in order to improve both yield and resistance to pests or herbicides, is gaining a high degree of public acceptance. The genetically modified tomato, CGN-89564-2, was the first commercially grown, genetically engineered crop product to be granted a license for human consumption. Additionally, DNA molecular marker technology is important for preservation, identification, evaluation, mining, and innovation of plant germplasm resources. The introduction of a genetically modified fruit paved the way for the use of GMOs in food. Currently, genetic modification is witnessing a widespread adoption.

Region with largest share:

North America is projected to hold the largest market share owing to the substantial number of biopharmaceutical manufacturing participants which are headquartered in the U.S. The presence of effective regulatory bodies to monitor the various ethical and scientific concerns pertaining to the use of technology has also driven the regional growth. For instance, this country witnessed the 1st FDA approval for U.S. gene therapy treatment. The treatment was developed for leukemia, as a result of a collaboration between the University of Pennsylvania and Novartis Corp. This, in turn, is anticipated to nurture the implementation of rDNA techniques in the region.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR due to the presence of low-cost manufacturing centers in the Asian economies, such as China. Japan is recognized as one of the world’s largest per capita importers of food and feed developed using modern biotechnology tools. Japan’s regulatory system for GE crops continues to improve. Moreover, there is no significant trade barrier in Japan to hamper GE products export from western countries. As a result, Asia Pacific is expected to emerge as the fastest-growing regional market.

Key players in the market

Some of the key players profiled in the Recombinant Deoxyribonucleic Acid (rDNA) Technology Market include Novartis AG, GlaxoSmithKline plc., Sanofi SA, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Pfizer Inc., Thermo Fisher Scientific, Inc., Biogen Inc., Biocon Limited, Novo Nordisk A/S, Merck KGaA, Amgen Inc., Boehringer Ingelheim, Chiron Corporation, Genscript Biotech, Horizon Discovery Group plc, Monsanto Company, and Profacgen.

Key developments:

In January 2022: Pfizer and Beam entered exclusive multi-target research collaboration to advance novel in vivo base editing programs for a range of rare diseases. Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with Beam’s leadership in base editing and mRNA/LNP delivery technologies.

In July 2020: GlaxoSmithKline plc and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements GSK’s existing mRNA capabilities with CureVac’s integrated mRNA platform.

Components Covered:
• Cloning Vector
• Expression System

Products Covered:
• Medical
• Non-Medical

Applications Covered:
• Food & Beverages
• Agriculture
• Therapeutics
• Healthcare & Disease
• Environment

End Users Covered:
• Biotechnology and Pharmaceutical Companies
• Diagnostic Laboratories
• Academic & Government Research Institutes
• Biochemical Industry

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan       
o China       
o India       
o Australia 
o New Zealand
o South Korea
o Rest of Asia Pacific   
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Select License Type

Allows one person to have access to the ordered product.The ordered product cannot be distributed to anyone else.
Allows the ordered product to be shared among a maximum of 5 people within your organisation.
Allows the product to be shared among all employees of your organisation at one particular location.
Allows the product to be shared among all employees of your organisation regardless of their geographical location.

WHY CHOOSE US ?

Assured Quality

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Free Customization

Adding more values to your product of interest.

Safe and Secure Access

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials